APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Fibrosis Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Pulmonary Fibrosis Drug Industry Growth and Trends Forecast to 2032

2 January 2026107 pages

Choose your research edition.

Industry ResearchPulmonary Fibrosis Drug Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Fibrosis Drug Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Pulmonary Fibrosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Fibrosis Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Fibrosis Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Pulmonary Fibrosis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Pulmonary Fibrosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Pulmonary Fibrosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Fibrosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pulmonary Fibrosis Drug include Merck & Co., Inc., Roche, MediciNova, Inc., Genentech, Inc., Galapagos NV, FibroGen, Inc., Cipla Inc., Bristol-Myers Squibb Company and Boehringer Ingelheim, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Pulmonary Fibrosis Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Pulmonary Fibrosis Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Pulmonary Fibrosis Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Pulmonary Fibrosis Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Pulmonary Fibrosis Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Pulmonary Fibrosis Drug Market by Company

Merck & Co., Inc.

Roche

MediciNova, Inc.

Genentech, Inc.

Galapagos NV

FibroGen, Inc.

Cipla Inc.

Bristol-Myers Squibb Company

Boehringer Ingelheim

Biogen

Pulmonary Fibrosis Drug Segment by Type

Pirfenidone

Nintedanib

Pulmonary Fibrosis Drug Segment by Application

Hospital

Clinic

Pulmonary Fibrosis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Fibrosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Fibrosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Fibrosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pulmonary Fibrosis Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Pulmonary Fibrosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Pirfenidone Table 2. Major Company of Nintedanib Table 3. Global Pulmonary Fibrosis Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Pulmonary Fibrosis Drug Sales by Type (2021-2026) & (K Units) Table 5. Global Pulmonary Fibrosis Drug Sales Market Share in Volume by Type (2021-2026) Table 6. Global Pulmonary Fibrosis Drug Sales by Type (2021-2026) & (US$ Million) Table 7. Global Pulmonary Fibrosis Drug Sales Market Share in Value by Type (2021-2026) Table 8. Global Pulmonary Fibrosis Drug Price by Type (2021-2026) & (US$/Unit) Table 9. Global Pulmonary Fibrosis Drug Sales by Type (2027-2032) & (K Units) Table 10. Global Pulmonary Fibrosis Drug Sales Market Share in Volume by Type (2027-2032) Table 11. Global Pulmonary Fibrosis Drug Sales by Type (2027-2032) & (US$ Million) Table 12. Global Pulmonary Fibrosis Drug Sales Market Share in Value by Type (2027-2032) Table 13. Global Pulmonary Fibrosis Drug Price by Type (2027-2032) & (US$/Unit) Table 14. North America Pulmonary Fibrosis Drug Sales by Type (2021-2026) & (K Units) Table 15. North America Pulmonary Fibrosis Drug Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Pulmonary Fibrosis Drug Sales by Type (2021-2026) & (K Units) Table 17. Europe Pulmonary Fibrosis Drug Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Pulmonary Fibrosis Drug Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Pulmonary Fibrosis Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Pulmonary Fibrosis Drug Sales by Type (2021-2026) & (K Units) Table 21. Latin America Pulmonary Fibrosis Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Pulmonary Fibrosis Drug Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Pulmonary Fibrosis Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Pulmonary Fibrosis Drug Industry Trends Table 25. Pulmonary Fibrosis Drug Industry Drivers Table 26. Pulmonary Fibrosis Drug Industry Opportunities and Challenges Table 27. Pulmonary Fibrosis Drug Industry Restraints Table 28. Global Pulmonary Fibrosis Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Pulmonary Fibrosis Drug Revenue Market Share by Company (2021-2026) Table 30. Global Pulmonary Fibrosis Drug Sales by Company (2021-2026) & (K Units) Table 31. Global Pulmonary Fibrosis Drug Sales Share by Company (2021-2026) Table 32. Global Pulmonary Fibrosis Drug Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Pulmonary Fibrosis Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Pulmonary Fibrosis Drug Major Company Production Sites and Headquarters Table 35. Global Pulmonary Fibrosis Drug Company, Product Type & Application Table 36. Global Pulmonary Fibrosis Drug Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Pulmonary Fibrosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Pulmonary Fibrosis Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Pulmonary Fibrosis Drug Sales by Region (2021-2026) & (K Units) Table 41. Global Pulmonary Fibrosis Drug Sales Market Share in Volume by Region (2021-2026) Table 42. Global Pulmonary Fibrosis Drug Sales by Region (2021-2026) & (US$ Million) Table 43. Global Pulmonary Fibrosis Drug Sales Market Share in Value by Region (2021-2026) Table 44. Global Pulmonary Fibrosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Pulmonary Fibrosis Drug Sales by Region (2027-2032) & (K Units) Table 46. Global Pulmonary Fibrosis Drug Sales Market Share in Volume by Region (2027-2032) Table 47. Global Pulmonary Fibrosis Drug Sales by Region (2027-2032) & (US$ Million) Table 48. Global Pulmonary Fibrosis Drug Sales Market Share in Value by Region (2027-2032) Table 49. Global Pulmonary Fibrosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Pulmonary Fibrosis Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Pulmonary Fibrosis Drug Sales by Application (2021-2026) & (K Units) Table 52. Global Pulmonary Fibrosis Drug Sales Market Share in Volume by Application (2021-2026) Table 53. Global Pulmonary Fibrosis Drug Sales by Application (2021-2026) & (US$ Million) Table 54. Global Pulmonary Fibrosis Drug Sales Market Share in Value by Application (2021-2026) Table 55. Global Pulmonary Fibrosis Drug Price by Application (2021-2026) & (US$/Unit) Table 56. Global Pulmonary Fibrosis Drug Sales by Application (2027-2032) & (K Units) Table 57. Global Pulmonary Fibrosis Drug Sales Market Share in Volume by Application (2027-2032) Table 58. Global Pulmonary Fibrosis Drug Sales by Application (2027-2032) & (US$ Million) Table 59. Global Pulmonary Fibrosis Drug Sales Market Share in Value by Application (2027-2032) Table 60. Global Pulmonary Fibrosis Drug Price by Application (2027-2032) & (US$/Unit) Table 61. North America Pulmonary Fibrosis Drug Sales by Application (2021-2026) & (K Units) Table 62. North America Pulmonary Fibrosis Drug Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Pulmonary Fibrosis Drug Sales by Application (2021-2026) & (K Units) Table 64. Europe Pulmonary Fibrosis Drug Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Pulmonary Fibrosis Drug Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Pulmonary Fibrosis Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Pulmonary Fibrosis Drug Sales by Application (2021-2026) & (K Units) Table 68. Latin America Pulmonary Fibrosis Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Pulmonary Fibrosis Drug Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Pulmonary Fibrosis Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Merck & Co., Inc. Company Information Table 72. Merck & Co., Inc. Business Overview Table 73. Merck & Co., Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Merck & Co., Inc. Pulmonary Fibrosis Drug Product Portfolio Table 75. Merck & Co., Inc. Recent Development Table 76. Roche Company Information Table 77. Roche Business Overview Table 78. Roche Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Roche Pulmonary Fibrosis Drug Product Portfolio Table 80. Roche Recent Development Table 81. MediciNova, Inc. Company Information Table 82. MediciNova, Inc. Business Overview Table 83. MediciNova, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. MediciNova, Inc. Pulmonary Fibrosis Drug Product Portfolio Table 85. MediciNova, Inc. Recent Development Table 86. Genentech, Inc. Company Information Table 87. Genentech, Inc. Business Overview Table 88. Genentech, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Genentech, Inc. Pulmonary Fibrosis Drug Product Portfolio Table 90. Genentech, Inc. Recent Development Table 91. Galapagos NV Company Information Table 92. Galapagos NV Business Overview Table 93. Galapagos NV Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Galapagos NV Pulmonary Fibrosis Drug Product Portfolio Table 95. Galapagos NV Recent Development Table 96. FibroGen, Inc. Company Information Table 97. FibroGen, Inc. Business Overview Table 98. FibroGen, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. FibroGen, Inc. Pulmonary Fibrosis Drug Product Portfolio Table 100. FibroGen, Inc. Recent Development Table 101. Cipla Inc. Company Information Table 102. Cipla Inc. Business Overview Table 103. Cipla Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Cipla Inc. Pulmonary Fibrosis Drug Product Portfolio Table 105. Cipla Inc. Recent Development Table 106. Bristol-Myers Squibb Company Company Information Table 107. Bristol-Myers Squibb Company Business Overview Table 108. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Portfolio Table 110. Bristol-Myers Squibb Company Recent Development Table 111. Boehringer Ingelheim Company Information Table 112. Boehringer Ingelheim Business Overview Table 113. Boehringer Ingelheim Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Boehringer Ingelheim Pulmonary Fibrosis Drug Product Portfolio Table 115. Boehringer Ingelheim Recent Development Table 116. Biogen Company Information Table 117. Biogen Business Overview Table 118. Biogen Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Biogen Pulmonary Fibrosis Drug Product Portfolio Table 120. Biogen Recent Development Table 121. North America Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 122. North America Pulmonary Fibrosis Drug Sales by Country (2021-2026) & (K Units) Table 123. North America Pulmonary Fibrosis Drug Sales Market Share by Country (2021-2026) Table 124. North America Pulmonary Fibrosis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 125. North America Pulmonary Fibrosis Drug Sales Market Share Forecast by Country (2027-2032) Table 126. North America Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. North America Pulmonary Fibrosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 128. North America Pulmonary Fibrosis Drug Market Share by Country (2021-2026) Table 129. North America Pulmonary Fibrosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. North America Pulmonary Fibrosis Drug Market Share Forecast by Country (2027-2032) Table 131. Europe Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 132. Europe Pulmonary Fibrosis Drug Sales by Country (2021-2026) & (K Units) Table 133. Europe Pulmonary Fibrosis Drug Sales Market Share by Country (2021-2026) Table 134. Europe Pulmonary Fibrosis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 135. Europe Pulmonary Fibrosis Drug Sales Market Share Forecast by Country (2027-2032) Table 136. Europe Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Europe Pulmonary Fibrosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 138. Europe Pulmonary Fibrosis Drug Market Share by Country (2021-2026) Table 139. Europe Pulmonary Fibrosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Europe Pulmonary Fibrosis Drug Market Share Forecast by Country (2027-2032) Table 141. Asia-Pacific Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 142. Asia-Pacific Pulmonary Fibrosis Drug Sales by Country (2021-2026) & (K Units) Table 143. Asia-Pacific Pulmonary Fibrosis Drug Sales Market Share by Country (2021-2026) Table 144. Asia-Pacific Pulmonary Fibrosis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 145. Asia-Pacific Pulmonary Fibrosis Drug Sales Market Share Forecast by Country (2027-2032) Table 146. Asia-Pacific Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Asia-Pacific Pulmonary Fibrosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 148. Asia-Pacific Pulmonary Fibrosis Drug Market Share by Country (2021-2026) Table 149. Asia-Pacific Pulmonary Fibrosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Asia-Pacific Pulmonary Fibrosis Drug Market Share Forecast by Country (2027-2032) Table 151. Latin America Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 152. Latin America Pulmonary Fibrosis Drug Sales by Country (2021-2026) & (K Units) Table 153. Latin America Pulmonary Fibrosis Drug Sales Market Share by Country (2021-2026) Table 154. Latin America Pulmonary Fibrosis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 155. Latin America Pulmonary Fibrosis Drug Sales Market Share Forecast by Country (2027-2032) Table 156. Latin America Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Latin America Pulmonary Fibrosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 158. Latin America Pulmonary Fibrosis Drug Market Share by Country (2021-2026) Table 159. Latin America Pulmonary Fibrosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Latin America Pulmonary Fibrosis Drug Market Share Forecast by Country (2027-2032) Table 161. Middle East and Africa Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 162. Middle East and Africa Pulmonary Fibrosis Drug Sales by Country (2021-2026) & (K Units) Table 163. Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share by Country (2021-2026) Table 164. Middle East and Africa Pulmonary Fibrosis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 165. Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share Forecast by Country (2027-2032) Table 166. Middle East and Africa Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Middle East and Africa Pulmonary Fibrosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 168. Middle East and Africa Pulmonary Fibrosis Drug Market Share by Country (2021-2026) Table 169. Middle East and Africa Pulmonary Fibrosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Middle East and Africa Pulmonary Fibrosis Drug Market Share Forecast by Country (2027-2032) Table 171. Key Raw Materials Table 172. Raw Materials Key Suppliers Table 173. Pulmonary Fibrosis Drug Distributors List Table 174. Pulmonary Fibrosis Drug Customers List Table 175. Research Programs/Design for This Report Table 176. Authors List of This Report Table 177. Secondary Sources Table 178. Primary Sources List of Figures Figure 1. Pulmonary Fibrosis Drug Image Figure 2. Global Pulmonary Fibrosis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Fibrosis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Pulmonary Fibrosis Drug Sales (2021-2032) & (K Units) Figure 5. Pirfenidone Image Figure 6. Global Pirfenidone Sales YoY Growth (2021-2032) & (K Units) Figure 7. Nintedanib Image Figure 8. Global Nintedanib Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Pulmonary Fibrosis Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Pulmonary Fibrosis Drug Market Share by Type 2025 VS 2032 Figure 11. North America Pulmonary Fibrosis Drug Sales Market Share in Volume by Type in 2025 Figure 12. North America Pulmonary Fibrosis Drug Sales Market Share in Value by Type in 2025 Figure 13. Europe Pulmonary Fibrosis Drug Sales Market Share in Volume by Type in 2025 Figure 14. Europe Pulmonary Fibrosis Drug Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Pulmonary Fibrosis Drug Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Pulmonary Fibrosis Drug Sales Market Share in Value by Type in 2025 Figure 17. Latin America Pulmonary Fibrosis Drug Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Pulmonary Fibrosis Drug Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Pulmonary Fibrosis Drug Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital Image Figure 24. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 25. Clinic Image Figure 26. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 27. Global Pulmonary Fibrosis Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Pulmonary Fibrosis Drug Market Share by Application 2025 VS 2032 Figure 29. North America Pulmonary Fibrosis Drug Sales Market Share in Volume by Application in 2025 Figure 30. North America Pulmonary Fibrosis Drug Sales Market Share in Value by Application in 2025 Figure 31. Europe Pulmonary Fibrosis Drug Sales Market Share in Volume by Application in 2025 Figure 32. Europe Pulmonary Fibrosis Drug Sales Market Share in Value by Application in 2025 Figure 33. Asia-Pacific Pulmonary Fibrosis Drug Sales Market Share in Volume by Application in 2025 Figure 34. Asia-Pacific Pulmonary Fibrosis Drug Sales Market Share in Value by Application in 2025 Figure 35. Latin America Pulmonary Fibrosis Drug Sales Market Share in Volume by Application in 2025 Figure 36. Latin America Pulmonary Fibrosis Drug Sales Market Share in Value by Application in 2025 Figure 37. Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share in Volume by Application in 2025 Figure 38. Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share in Value by Application in 2025 Figure 39. North America Pulmonary Fibrosis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 40. North America Pulmonary Fibrosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 41. North America Pulmonary Fibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. North America Pulmonary Fibrosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Pulmonary Fibrosis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. Europe Pulmonary Fibrosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Pulmonary Fibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Pulmonary Fibrosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Asia-Pacific Pulmonary Fibrosis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Asia-Pacific Pulmonary Fibrosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Pulmonary Fibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Asia-Pacific Pulmonary Fibrosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Pulmonary Fibrosis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Latin America Pulmonary Fibrosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Pulmonary Fibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Pulmonary Fibrosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Middle East and Africa Pulmonary Fibrosis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Middle East and Africa Pulmonary Fibrosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Pulmonary Fibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Middle East and Africa Pulmonary Fibrosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Pulmonary Fibrosis Drug Value Chain Figure 60. Key Raw Materials Price Figure 61. Manufacturing Cost Structure Figure 62. Pulmonary Fibrosis Drug Production Mode & Process Figure 63. Direct Comparison with Distribution Share Figure 64. Distributors Profiles Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Pirfenidone
  • Nintedanib
Applications
  • Hospital
  • Clinic
Companies covered
  • Merck & Co., Inc.
  • Roche
  • MediciNova, Inc.
  • Genentech, Inc.
  • Galapagos NV
  • FibroGen, Inc.
  • Cipla Inc.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim
  • Biogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pulmonary Fibrosis Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Pulmonary Fibrosis Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Pulmonary Fibrosis Drug Market by Type
  6. 1.3.1 Pirfenidone
  7. 1.3.2 Nintedanib
  8. 1.4 Global Pulmonary Fibrosis Drug Market Size by Type
  9. 1.4.1 Global Pulmonary Fibrosis Drug Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Pulmonary Fibrosis Drug Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Pulmonary Fibrosis Drug Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Pulmonary Fibrosis Drug Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Pulmonary Fibrosis Drug Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Pulmonary Fibrosis Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Pulmonary Fibrosis Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Pulmonary Fibrosis Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Pulmonary Fibrosis Drug Industry Trends
  2. 2.2 Pulmonary Fibrosis Drug Industry Drivers
  3. 2.3 Pulmonary Fibrosis Drug Industry Opportunities and Challenges
  4. 2.4 Pulmonary Fibrosis Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Pulmonary Fibrosis Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Pulmonary Fibrosis Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Pulmonary Fibrosis Drug Price (2021-2026)
  4. 3.4 Global Pulmonary Fibrosis Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pulmonary Fibrosis Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Pulmonary Fibrosis Drug Company, Product Type & Application
  7. 3.7 Global Pulmonary Fibrosis Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pulmonary Fibrosis Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pulmonary Fibrosis Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pulmonary Fibrosis Drug Tier 1, Tier 2, and Tier 3
4 Pulmonary Fibrosis Drug Regional Status and Outlook
  1. 4.1 Global Pulmonary Fibrosis Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Pulmonary Fibrosis Drug Historic Market Size by Region
  3. 4.2.1 Global Pulmonary Fibrosis Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Pulmonary Fibrosis Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Pulmonary Fibrosis Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Pulmonary Fibrosis Drug Forecasted Market Size by Region
  7. 4.3.1 Global Pulmonary Fibrosis Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Pulmonary Fibrosis Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Pulmonary Fibrosis Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Pulmonary Fibrosis Drug by Application
  1. 5.1 Pulmonary Fibrosis Drug Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Pulmonary Fibrosis Drug Market Size by Application
  5. 5.2.1 Global Pulmonary Fibrosis Drug Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Pulmonary Fibrosis Drug Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Pulmonary Fibrosis Drug Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Pulmonary Fibrosis Drug Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Pulmonary Fibrosis Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Pulmonary Fibrosis Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Pulmonary Fibrosis Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Pulmonary Fibrosis Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Merck & Co., Inc.
  2. 6.1.1 Merck & Co., Inc. Company Information
  3. 6.1.2 Merck & Co., Inc. Business Overview
  4. 6.1.3 Merck & Co., Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Merck & Co., Inc. Pulmonary Fibrosis Drug Product Portfolio
  6. 6.1.5 Merck & Co., Inc. Recent Developments
  7. 6.2 Roche
  8. 6.2.1 Roche Company Information
  9. 6.2.2 Roche Business Overview
  10. 6.2.3 Roche Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Roche Pulmonary Fibrosis Drug Product Portfolio
  12. 6.2.5 Roche Recent Developments
  13. 6.3 MediciNova, Inc.
  14. 6.3.1 MediciNova, Inc. Company Information
  15. 6.3.2 MediciNova, Inc. Business Overview
  16. 6.3.3 MediciNova, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 MediciNova, Inc. Pulmonary Fibrosis Drug Product Portfolio
  18. 6.3.5 MediciNova, Inc. Recent Developments
  19. 6.4 Genentech, Inc.
  20. 6.4.1 Genentech, Inc. Company Information
  21. 6.4.2 Genentech, Inc. Business Overview
  22. 6.4.3 Genentech, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Genentech, Inc. Pulmonary Fibrosis Drug Product Portfolio
  24. 6.4.5 Genentech, Inc. Recent Developments
  25. 6.5 Galapagos NV
  26. 6.5.1 Galapagos NV Company Information
  27. 6.5.2 Galapagos NV Business Overview
  28. 6.5.3 Galapagos NV Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Galapagos NV Pulmonary Fibrosis Drug Product Portfolio
  30. 6.5.5 Galapagos NV Recent Developments
  31. 6.6 FibroGen, Inc.
  32. 6.6.1 FibroGen, Inc. Company Information
  33. 6.6.2 FibroGen, Inc. Business Overview
  34. 6.6.3 FibroGen, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 FibroGen, Inc. Pulmonary Fibrosis Drug Product Portfolio
  36. 6.6.5 FibroGen, Inc. Recent Developments
  37. 6.7 Cipla Inc.
  38. 6.7.1 Cipla Inc. Company Information
  39. 6.7.2 Cipla Inc. Business Overview
  40. 6.7.3 Cipla Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Cipla Inc. Pulmonary Fibrosis Drug Product Portfolio
  42. 6.7.5 Cipla Inc. Recent Developments
  43. 6.8 Bristol-Myers Squibb Company
  44. 6.8.1 Bristol-Myers Squibb Company Company Information
  45. 6.8.2 Bristol-Myers Squibb Company Business Overview
  46. 6.8.3 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Portfolio
  48. 6.8.5 Bristol-Myers Squibb Company Recent Developments
  49. 6.9 Boehringer Ingelheim
  50. 6.9.1 Boehringer Ingelheim Company Information
  51. 6.9.2 Boehringer Ingelheim Business Overview
  52. 6.9.3 Boehringer Ingelheim Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Boehringer Ingelheim Pulmonary Fibrosis Drug Product Portfolio
  54. 6.9.5 Boehringer Ingelheim Recent Developments
  55. 6.10 Biogen
  56. 6.10.1 Biogen Company Information
  57. 6.10.2 Biogen Business Overview
  58. 6.10.3 Biogen Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Biogen Pulmonary Fibrosis Drug Product Portfolio
  60. 6.10.5 Biogen Recent Developments
7 North America by Country
  1. 7.1 North America Pulmonary Fibrosis Drug Sales by Country
  2. 7.1.1 North America Pulmonary Fibrosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Pulmonary Fibrosis Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Pulmonary Fibrosis Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Pulmonary Fibrosis Drug Market Size by Country
  6. 7.2.1 North America Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Pulmonary Fibrosis Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Pulmonary Fibrosis Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Pulmonary Fibrosis Drug Sales by Country
  2. 8.1.1 Europe Pulmonary Fibrosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Pulmonary Fibrosis Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Pulmonary Fibrosis Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Pulmonary Fibrosis Drug Market Size by Country
  6. 8.2.1 Europe Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Pulmonary Fibrosis Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Pulmonary Fibrosis Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Pulmonary Fibrosis Drug Sales by Country
  2. 9.1.1 Asia-Pacific Pulmonary Fibrosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Pulmonary Fibrosis Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Pulmonary Fibrosis Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Pulmonary Fibrosis Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Pulmonary Fibrosis Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Pulmonary Fibrosis Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Pulmonary Fibrosis Drug Sales by Country
  2. 10.1.1 South America Pulmonary Fibrosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Pulmonary Fibrosis Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Pulmonary Fibrosis Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Pulmonary Fibrosis Drug Market Size by Country
  6. 10.2.1 South America Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Pulmonary Fibrosis Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Pulmonary Fibrosis Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Pulmonary Fibrosis Drug Sales by Country
  2. 11.1.1 Middle East and Africa Pulmonary Fibrosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Pulmonary Fibrosis Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Pulmonary Fibrosis Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Pulmonary Fibrosis Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Pulmonary Fibrosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Pulmonary Fibrosis Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Pulmonary Fibrosis Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Pulmonary Fibrosis Drug Value Chain Analysis
  2. 12.1.1 Pulmonary Fibrosis Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Pulmonary Fibrosis Drug Production Mode & Process
  7. 12.2 Pulmonary Fibrosis Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Pulmonary Fibrosis Drug Distributors
  10. 12.2.3 Pulmonary Fibrosis Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst